ImpediMed Limited (ASX: IPD) has reached a service agreement with Institut Curie for the first prospective, multi-centre, clinical trial that will use its L-Dex® device for assessment of unilateral lymphoedema.
Institut Curie is one of Europe’s leading oncology research centres with a reputation for accelerating the advancement of new clinical tools.
The five-year, randomised controlled trial will take place at five centres in France to study early detection and treatment of lymphoedema related to breast cancer.
This will follow 800 women for two years with L-Dex as the primary measurement criteria.
Patients will be measured before cancer treatment, and every four to six months, up to twenty-four months post-treatment.
This represents the first major trial in the field of the prevention of lymphoedema following the treatment of breast cancer in France and is the first step in changing clinical practice in France to one of a pre-emptive care model.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.